Entrada Therapeutics (NASDAQ: TRDA) — Company Overview, News & Financial Data
Entrada Therapeutics develops innovative therapies to engage intracellular targets for treating serious diseases, enhancing patient care.
Entrada Therapeutics
Entrada Therapeutics (NASDAQ:TRDA) is a biotechnology firm focused on the development of innovative therapies. The company specializes in creating drugs designed to engage intracellular targets, aiming to treat a broad range of diseases, including neuromuscular conditions and other serious ailments. Entrada Therapeutics is leveraging its proprietary platform to advance a portfolio of oligonucleotide and peptide therapeutics aimed at addressing unmet medical needs. With a commitment to science and patient care driving its operations, the firm is dedicated to pushing the boundaries of medicine to improve the lives of patients worldwide.
Snapshot
Operations
Products and/or services of Entrada Therapeutics
- Developing an intracellular biologics delivery platform aimed at transforming the treatment of devastating diseases.
- Focusing on a Duchenne Muscular Dystrophy (DMD) program, leveraging their platform to address this genetic disorder.
- Advancing programs targeting Myotonic Dystrophy Type 1, utilizing novel therapeutics for this neuromuscular disease.
- Creating a broad pipeline of endosomal escape vehicle (EEV™)-fueled therapies for various diseases.
- Offering research and development services to create custom intracellular delivery solutions for biopharmaceutical companies.
- Exploring potential treatments for other rare diseases through their proprietary technology platform.
Entrada Therapeutics executive team
- Dipal DoshiCEO & Director
- Nathan J. DowdenPresident & COO
- Natarajan SethuramanPresident of Research & Development
- Kory James WentworthCFO & Treasurer
- Jared CohenGeneral Counsel
- Karla MacDonaldChief Corporate Affairs Officer
- Kevin HealySenior Vice President of Regulatory Affairs
- Sandeep BasnetHead of Information Technology
Latest news about Entrada Therapeutics
Key financials
Reported results for Entrada Therapeutics, in USD.
- Market cap
- 183.8M
- Revenue (TTM)
- 4.7M
- P/E ratio
- —
- EPS (diluted, TTM)
- -4.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 25.4M | -156M | -143.8M | |
| 210.8M | 47M | 65.6M | |
| 129M | -3.2M | -6.7M | |
| 25.3M | -97.2M | -87.5M |